Serine biosynthesis and transport defects

Molecular Genetics and Metabolism

Volumn 118, Issue 3, 2016, Pages 153-159

  El Hattab, Ayman W ^a  

^a TAWAM HOSPITAL   (United Arab Emirates)

Author keywords

ASCT1; Neu Laxova syndrome; Phosphoglycerate dehydrogenase (PGDH); Phosphoserine aminotransferase (PSAT); Phosphoserine phosphatase (PSP); Serine transporter; SLC1A4 gene

Indexed keywords

SERINE; AMINO ACID TRANSPORTER; SLC1A4 PROTEIN, HUMAN;

AMINO ACID DEFICIENCY; AMINO ACID METABOLISM; AMINO ACID TRANSPORT; BIOCHEMISTRY; CHILDHOOD DISEASE; CHILDHOOD SERINE BIOSYNTHESIS DEFECT; CONGENITAL MALFORMATION; INFANT DISEASE; INFANTILE SERINE BIOSYNTHESIS DEFECT; NEU LAXOVA SYNDROME; PHENOTYPE; PRIORITY JOURNAL; REVIEW; BIOSYNTHESIS; BRAIN DISEASE; CHILD; DEFICIENCY; ENZYMOLOGY; HUMAN; ICHTHYOSIS; INTRAUTERINE GROWTH RETARDATION; LIMB MALFORMATION; METABOLISM; MICROCEPHALY; MULTIPLE MALFORMATION SYNDROME; NERVE CELL; PROTEIN TRANSPORT;

ABNORMALITIES, MULTIPLE; AMINO ACID TRANSPORT SYSTEM ASC; BRAIN DISEASES; CHILD; FETAL GROWTH RETARDATION; HUMANS; ICHTHYOSIS; LIMB DEFORMITIES, CONGENITAL; MICROCEPHALY; NEURONS; PROTEIN TRANSPORT; SERINE;

EID: 84964994281     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2016.04.010     Document Type: Review

References (46)

1. Jaeken J. Disorders of Proline and Serine Metabolism. Inborn Metabolic Diseases [Internet] 2012, 357-362. Springer Berlin Heidelberg, [cited 2016 Mar 19]. (Available from:) http://link.springer.com/chapter/10.1007/978-3-642-15720-2_25. J.-M. Saudubray, B.G. van den, J.H. Walter (Eds.).
2. El-Hattab A.W., Shaheen R., Hertecant J., Galadari H.I., Albaqawi B.S., Nabil A., et al. On the phenotypic spectrum of serine biosynthesis defects. J. Inherit. Metab. Dis. 2016 Mar 10.
3. Damseh N., Simonin A., Jalas C., Picoraro J.A., Shaag A., Cho M.T., et al. Mutations in SLC1A4, encoding the brain serine transporter, are associated with developmental delay, microcephaly and hypomyelination. J. Med. Genet. 2015 Aug, 52(8):541-547.
4. Heimer G., Marek-Yagel D., Eyal E., Barel O., Oz Levi D., Hoffmann C., et al. SLC1A4 mutations cause a novel disorder of intellectual disability, progressive microcephaly, spasticity and thin corpus callosum. Clin. Genet. 2015 Oct, 88(4):327-335.
5. Srour M., Hamdan F.F., Gan-Or Z., Labuda D., Nassif C., Oskoui M., et al. A homozygous mutation in SLC1A4 in siblings with severe intellectual disability and microcephaly. Clin. Genet. 2015 Jul, 88(1):e1-e4.
6. van der Crabben S.N., Verhoeven-Duif N.M., Brilstra E.H., Van Maldergem L., Coskun T., Rubio-Gozalbo E., et al. An update on serine deficiency disorders. J. Inherit. Metab. Dis. 2013 Jul, 36(4):613-619.
7. Pamela C.C., Richard A.H., Denise R.F. Lippincotts Illustrated Reviews Biochemistry 2005, Lippincott Williams and Wilkins, Philadelphia.
8. Snyder S.H., Kim P.M. D-amino acids as putative neurotransmitters: focus on d-serine. Neurochem. Res. 2000 May, 25(5):553-560.
9. Furuya S., Watanabe M. Novel neuroglial and glioglial relationships mediated by l-serine metabolism. Arch. Histol. Cytol. 2003 May, 66(2):109-121.
10. Smith Q.R. Transport of glutamate and other amino acids at the blood-brain barrier. J. Nutr. 2000 Apr, 130(4S Suppl):1016S-1022S.
11. Yamasaki M., Yamada K., Furuya S., Mitoma J., Hirabayashi Y., Watanabe M. 3-Phosphoglycerate dehydrogenase, a key enzyme for l-serine biosynthesis, is preferentially expressed in the radial glia/astrocyte lineage and olfactory ensheathing glia in the mouse brain. J. Neurosci. 2001 Oct 1, 21(19):7691-7704.
12. Furuya S. An essential role for de novo biosynthesis of l-serine in CNS development. Asia Pac. J. Clin. Nutr. 2008, 17(Suppl. 1):312-315.
13. Kanai Y., Clémençon B., Simonin A., Leuenberger M., Lochner M., Weisstanner M., et al. The SLC1 high-affinity glutamate and neutral amino acid transporter family. Mol. Asp. Med. 2013 Jun, 34(2-3):108-120.
14. Sakai K., Shimizu H., Koike T., Furuya S., Watanabe M. Neutral amino acid transporter ASCT1 is preferentially expressed in L-Ser-synthetic/storing glial cells in the mouse brain with transient expression in developing capillaries. J. Neurosci. 2003 Jan 15, 23(2):550-560.
15. Yamamoto T., Nishizaki I., Furuya S., Hirabayashi Y., Takahashi K., Okuyama S., et al. Characterization of rapid and high-affinity uptake of l-serine in neurons and astrocytes in primary culture. FEBS Lett. 2003 Jul 31, 548(1-3):69-73.
16. Neu R.L., Kajii T., Gardner L.I., Nagyfy S.F. A lethal syndrome of microcephaly with multiple congenital anomalies in three siblings. Pediatrics 1971 Mar, 47(3):610-612.
17. Laxova R., Ohara P.T., Timothy J.A. A further example of a lethal autosomal recessive condition in sibs. J. Ment. Defic. Res. 1972 Jun, 16(2):139-143.
18. Jones KL, Jones MC, Campo M del. Smith's Recognizable Patterns of Human Malformation. 998 p; 9999.
19. Carder K.R., Fitzpatrick J.E., Weston W.L. What syndrome is this? Neu-Laxova syndrome. Pediatr. Dermatol. 2003 Feb, 20(1):78-80.
20. King J.A., Gardner V., Chen H., Blackburn W. Neu-Laxova syndrome: pathological evaluation of a fetus and review of the literature. Pediatr. Pathol. Lab. Med. J. Soc. Pediatr. Pathol. Affil. Int. Paediatr. Pathol. Assoc. 1995 Feb, 15(1):57-79.
21. Manning M.A., Cunniff C.M., Colby C.E., El-Sayed Y.Y., Hoyme H.E. Neu-Laxova syndrome: detailed prenatal diagnostic and post-mortem findings and literature review. Am. J. Med. Genet. A 2004 Mar 15, 125A(3):240-249.
22. Shapiro I., Borochowitz Z., Degani S., Dar H., Ibschitz I., Sharf M. Neu-Laxova syndrome: prenatal ultrasonographic diagnosis, clinical and pathological studies, and new manifestations. Am. J. Med. Genet. 1992 Jun 1, 43(3):602-605.
23. Shaheen R., Rahbeeni Z., Alhashem A., Faqeih E., Zhao Q., Xiong Y., et al. Neu-Laxova syndrome, an inborn error of serine metabolism, is caused by mutations in PHGDH. Am. J. Hum. Genet. 2014 Jun 5, 94(6):898-904.
24. Acuna-Hidalgo R., Schanze D., Kariminejad A., Nordgren A., Kariminejad M.H., Conner P., et al. Neu-Laxova syndrome is a heterogeneous metabolic disorder caused by defects in enzymes of the l-serine biosynthesis pathway. Am. J. Hum. Genet. 2014 Sep 4, 95(3):285-293.
25. Mattos E.P., da Silva A.A., Magalhães J.A.A., Leite J.C.L., Leistner-Segal S., Gus-Kessler R., et al. Identification of a premature stop codon mutation in the PHGDH gene in severe Neu-Laxova syndrome-evidence for phenotypic variability. Am. J. Med. Genet. A 2015 Jun, 167(6):1323-1329.
26. de Koning T.J., Duran M., Dorland L., Gooskens R., Van Schaftingen E., Jaeken J., et al. Beneficial effects of l-serine and glycine in the management of seizures in 3-phosphoglycerate dehydrogenase deficiency. Ann. Neurol. 1998 Aug, 44(2):261-265.
27. Häusler M.G., Jaeken J., Mönch E., Ramaekers V.T. Phenotypic heterogeneity and adverse effects of serine treatment in 3-phosphoglycerate dehydrogenase deficiency: report on two siblings. Neuropediatrics 2001 Aug, 32(4):191-195.
28. Jaeken J., Detheux M., Van Maldergem L., Foulon M., Carchon H., Van Schaftingen E. 3-Phosphoglycerate dehydrogenase deficiency: an inborn error of serine biosynthesis. Arch. Dis. Child. 1996 Jun, 74(6):542-545.
29. Klomp L.W., de Koning T.J., Malingré H.E., van Beurden E.A., Brink M., Opdam F.L., et al. Molecular characterization of 3-phosphoglycerate dehydrogenase deficiency-a neurometabolic disorder associated with reduced l-serine biosynthesis. Am. J. Hum. Genet. 2000 Dec, 67(6):1389-1399.
30. Pineda M., Vilaseca M.A., Artuch R., Santos S., García González M.M., Aracil A., et al. 3-Phosphoglycerate dehydrogenase deficiency in a patient with West syndrome. Dev. Med. Child Neurol. 2000 Sep, 42(9):629-633.
31. Hart C.E., Race V., Achouri Y., Wiame E., Sharrard M., Olpin S.E., et al. Phosphoserine aminotransferase deficiency: a novel disorder of the serine biosynthesis pathway. Am. J. Hum. Genet. 2007 May, 80(5):931-937.
32. Jaeken J., Detheux M., Fryns J.P., Collet J.F., Alliet P., Van Schaftingen E. Phosphoserine phosphatase deficiency in a patient with Williams syndrome. J. Med. Genet. 1997 Jul, 34(7):594-596.
33. Veiga-da-Cunha M., Collet J.-F., Prieur B., Jaeken J., Peeraer Y., Rabbijns A., et al. Mutations responsible for 3-phosphoserine phosphatase deficiency. Eur. J. Hum. Genet. 2004 Feb, 12(2):163-166.
34. Tabatabaie L., Klomp L.W.J., Rubio-Gozalbo M.E., Spaapen L.J.M., AM H., Dorland L., et al. Expanding the clinical spectrum of 3-phosphoglycerate dehydrogenase deficiency. J. Inherit. Metab. Dis. 2011 Feb, 34(1):181-184.
35. Méneret A., Wiame E., Marelli C., Lenglet T., Van Schaftingen E., Sedel F. A serine synthesis defect presenting with a Charcot-Marie-Tooth-like polyneuropathy. Arch. Neurol. 2012 Jul, 69(7):908-911.
36. Vincent J.B., Jamil T., Rafiq M.A., Anwar Z., Ayaz M., Hameed A., et al. Phosphoserine phosphatase (PSPH) gene mutation in an intellectual disability family from Pakistan. Clin. Genet. 2015 Mar, 87(3):296-298.
37. Horn D., Müller D., Thiele H., Kunze J. Extreme microcephaly, severe growth and mental retardation, flexion contractures, and ichthyotic skin in two brothers: a new syndrome or mild form of Neu-Laxova syndrome?. Clin. Dysmorphol. 1997 Oct, 6(4):323-328.
38. Labuschagne C.F., van den Broek N.J.F., Mackay G.M., Vousden K.H., Maddocks O.D.K. Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. Cell Rep. 2014 May 22, 7(4):1248-1258.
39. Possemato R., Marks K.M., Shaul Y.D., Pacold M.E., Kim D., Birsoy K., et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011 Aug 18, 476(7360):346-350.
40. Tedeschi P.M., Markert E.K., Gounder M., Lin H., Dvorzhinski D., Dolfi S.C., et al. Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell Death Dis. 2013, 4.
41. Vié N., Copois V., Bascoul-Mollevi C., Denis V., Bec N., Robert B., et al. Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells. Mol. Cancer 2008, 7:14.
42. Holleran W.M., Takagi Y., Uchida Y. Epidermal sphingolipids: metabolism, function, and roles in skin disorders. FEBS Lett. 2006 Oct 9, 580(23):5456-5466.
43. Yoshida K., Furuya S., Osuka S., Mitoma J., Shinoda Y., Watanabe M., et al. Targeted disruption of the mouse 3-phosphoglycerate dehydrogenase gene causes severe neurodevelopmental defects and results in embryonic lethality. J. Biol. Chem. 2004 Jan 30, 279(5):3573-3577.
44. de Koning T.J., Jaeken J., Pineda M., Van Maldergem L., Poll-The B.T., van der Knaap M.S. Hypomyelination and reversible white matter attenuation in 3-phosphoglycerate dehydrogenase deficiency. Neuropediatrics 2000 Dec, 31(6):287-292.
45. De Koning T.J., Duran M., Van Maldergem L., Pineda M., Dorland L., Gooskens R., et al. Congenital microcephaly and seizures due to 3-phosphoglycerate dehydrogenase deficiency: outcome of treatment with amino acids. J. Inherit. Metab. Dis. 2002 May, 25(2):119-125.
46. de Koning T.J., Klomp L.W.J., van Oppen A.C.C., Beemer F.A., Dorland L., van den Berg I., et al. Prenatal and early postnatal treatment in 3-phosphoglycerate-dehydrogenase deficiency. Lancet Lond. Engl. 2004 Dec 18, 364(9452):2221-2222.